MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)'s Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
5 Aug 2025 (48 Days) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
12 Feb 2025 Date | | - Cons. EPS | - EPS |
6 Nov 2024 Date | | - Cons. EPS | - EPS |
7 Aug 2024 Date | | - Cons. EPS | - EPS |
5 Aug 2025 (48 Days) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
12 Feb 2025 Date | | - Cons. EPS | - EPS |
6 Nov 2024 Date | | - Cons. EPS | - EPS |
7 Aug 2024 Date | | - Cons. EPS | - EPS |
Medical - Diagnostics & Research Industry | Healthcare Sector | Mr. James C. Foster J.D. CEO | XBER Exchange | US1598641074 ISIN |
US Country | 18,700 Employees | - Last Dividend | - Last Split | - IPO Date |
Charles River Laboratories International, Inc. stands as a pivotal organization within the pharmaceutical industry, providing a comprehensive suite of services encompassing drug discovery, non-clinical development, and safety testing. With a global footprint that extends across the United States, Europe, Canada, the Asia Pacific, and other international markets, the company is recognized for its integrated solutions that support the entire drug development cycle. It operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each tailored to meet the varied and complex needs of its clients. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to aiding its clients in the development of novel therapies and medicines through its vast expertise and comprehensive facilities.
Research Models and Services (RMS): This segment is integral to Charles River Laboratories' operations, producing and selling a wide variety of research rodents, including purpose-bred rats and mice. These are essential tools for researchers across the globe, enabling a myriad of scientific investigations and discoveries. Services offered within this segment also include:
Discovery and Safety Assessment (DSA): A critical segment that supports early-stage drug discovery and safety assessment. The DSA segment delivers:
Manufacturing Solutions (Manufacturing): This segment provides critical support in the quality control and testing of pharmaceuticals and consumer products. It encompasses: